Market Cap 313.78M
Revenue (ttm) 28.49M
Net Income (ttm) -13.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 1,030.71
Profit Margin -48.51%
Debt to Equity Ratio 1.34
Volume 166,300
Avg Vol 44,050
Day's Range N/A - N/A
Shares Out 11.97M
Stochastic %K 87%
Beta 0.94
Analysts Strong Sell
Price Target $64.67

Company Profile

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clin...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 204 7200
Address:
2200 Powell Street, Suite 310, Emeryville, United States
gvezzola
gvezzola Jun. 13 at 5:27 PM
Posted this on Yahoo Finance but wanted to share this here too. Yesterday I spoke to my brother who is a well respected Opthalmologist here in Europe and asked him about the Vabysmo medicine that is partially owned by $XOMA. He said that its his first choice over any competitors because it addresses two different pathologies of the eye. I think the sales of Vabysmo are gona increase drastically in the following years and $XOMA could very well benefit off of it.
0 · Reply
WeThePeople102
WeThePeople102 Jun. 7 at 9:53 PM
I have relatives who died by cancer, which is why I like to invest in biotech companies who research and develop cancer treatment. First, I bought $KNTE 20k shares @ $2.53, but this company was merged by $XOMA and off public. They refunded the amount of cash equal that I spent plus CVR, not bad at all. Second, after a long time watching, I finally bought $PMVP 3k shares @ $0.90 and $XLO 4k shares @ $0.67. Both companies have mc up to around $50M and phase 2 clinic trials, but cash on hand is bigger, mc. $PMVP is $185M, while $XLO is $85M. Hope they can safely exit Death Valley. Third, $MAIA data phase 2 looks promised, but cash is too few, around $10M. Keep watching.
2 · Reply
JarvisFlow
JarvisFlow May. 28 at 11:00 AM
HC Wainwright & Co. has updated their rating for XOMA Royalty ( $XOMA ) to Buy with a price target of 104.
0 · Reply
Drtymax
Drtymax May. 27 at 6:37 PM
$LADXD I’ll take 2 $XOMA shares for 1
0 · Reply
DonCorleone77
DonCorleone77 May. 27 at 12:27 PM
$XOMA Xoma purchases mezagitamab royalty, milestone rights for up to $30M XOMA Royalty and BioInvent International announced XOMA Royalty has purchased the future mezagitamab royalty and milestone interests held by BioInvent for $20M at closing, with a total transaction of up to $30M. The future royalty and milestone economics interest in mezagitamab originated from a 2003 cross-licensing agreement covering XOMA Royalty's legacy bacterial protein expression technology and BioInvent's n-CoDeR antibody library. Under the terms of XOMA Royalty's purchase of BioInvent's economic interest in mezagitamab, XOMA Royalty paid $20M to BioInvent at closing and will pay an additional $10M upon mezagitamab achieving a specific pre-defined regulatory milestone associated with receiving marketing approval in the IgA nephropathy indication from the U.S. Food and Drug Administration. With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to $16.25M from Takeda and mid-single digit royalties on future mezagitamab commercial sales.
0 · Reply
BioTechHealthX
BioTechHealthX May. 11 at 3:38 AM
$XOMA - With upcoming Phase 3 data from programs like seralutinib and ersodetug, XOMA Royalty’s royalty income could increase sharply in the coming quarters. https://biotechhealthx.com/biotech-news/investors-are-watching-xoma-ahead-of-2025s-major-clinical-readouts/
0 · Reply
Armonica423
Armonica423 May. 10 at 5:25 PM
$XOMA Big exposure for CYDY at 3 oncology conferences this week, do your dd research
0 · Reply
Zellchair
Zellchair May. 5 at 4:54 PM
$RPRX $LGND $XOMA I have written a long review of little-known peers to these companies. Under point “8. Closest comparable peers/stocks”, I write a whole paragraph about each company in tickers above, plus 4 more (Swedish and Canadian peers). Maybe someone here would appreciate reading at least that part.
0 · Reply
UNLV
UNLV Apr. 30 at 4:31 PM
Can’t see this one $XOMA https://stocktwits.com/NVDAMillionaire/message/601706454
1 · Reply
JarvisFlow
JarvisFlow Apr. 17 at 1:00 PM
Benchmark has updated their rating for XOMA Royalty ( $XOMA ) to Buy with a price target of 35.
0 · Reply
Latest News on XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends

Jun 18, 2025, 7:30 AM EDT - 7 days ago

XOMA Royalty Declares Quarterly Preferred Stock Dividends


XOMA Royalty Completes Sale of Kinnate Pipeline Assets

Apr 14, 2025, 7:30 AM EDT - 2 months ago

XOMA Royalty Completes Sale of Kinnate Pipeline Assets


XOMA Royalty to Present at Investor Conferences in March

Feb 24, 2025, 4:05 PM EST - 4 months ago

XOMA Royalty to Present at Investor Conferences in March


I Am Banking On The Silver Tsunami With Big Dividends

Oct 12, 2024, 10:30 AM EDT - 9 months ago

I Am Banking On The Silver Tsunami With Big Dividends

HROW THQ


XOMA Stock Dips Amidst Biotech Sector Decline

Oct 3, 2024, 3:53 PM EDT - 9 months ago

XOMA Stock Dips Amidst Biotech Sector Decline


My 2 Top Royalty Income Picks, Yields Up To 9.5%

Jul 19, 2024, 8:30 AM EDT - 1 year ago

My 2 Top Royalty Income Picks, Yields Up To 9.5%

KRP


XOMA Declares Quarterly Preferred Stock Dividends

Jun 20, 2024, 7:30 AM EDT - 1 year ago

XOMA Declares Quarterly Preferred Stock Dividends


Actym Therapeutics Appoints Thomas Smart as CEO

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB PGEN


XOMA Corporation Announces Closing of Tender Offer

Apr 3, 2024, 9:00 AM EDT - 1 year ago

XOMA Corporation Announces Closing of Tender Offer


XOMA to Present at Upcoming Investor Conferences in March

Feb 28, 2024, 7:30 AM EST - 1 year ago

XOMA to Present at Upcoming Investor Conferences in March


XOMA Announces Stock Repurchase Program of up to $50 Million

Jan 2, 2024, 7:30 AM EST - 1 year ago

XOMA Announces Stock Repurchase Program of up to $50 Million


I'm Buying Preferred Stocks Hand Over Fist

Dec 15, 2023, 8:30 AM EST - 1 year ago

I'm Buying Preferred Stocks Hand Over Fist

TDS


XOMA Added to the Russell 2000® and Russell 3000® Indexes

Jun 23, 2023, 6:14 PM EDT - 2 years ago

XOMA Added to the Russell 2000® and Russell 3000® Indexes


gvezzola
gvezzola Jun. 13 at 5:27 PM
Posted this on Yahoo Finance but wanted to share this here too. Yesterday I spoke to my brother who is a well respected Opthalmologist here in Europe and asked him about the Vabysmo medicine that is partially owned by $XOMA. He said that its his first choice over any competitors because it addresses two different pathologies of the eye. I think the sales of Vabysmo are gona increase drastically in the following years and $XOMA could very well benefit off of it.
0 · Reply
WeThePeople102
WeThePeople102 Jun. 7 at 9:53 PM
I have relatives who died by cancer, which is why I like to invest in biotech companies who research and develop cancer treatment. First, I bought $KNTE 20k shares @ $2.53, but this company was merged by $XOMA and off public. They refunded the amount of cash equal that I spent plus CVR, not bad at all. Second, after a long time watching, I finally bought $PMVP 3k shares @ $0.90 and $XLO 4k shares @ $0.67. Both companies have mc up to around $50M and phase 2 clinic trials, but cash on hand is bigger, mc. $PMVP is $185M, while $XLO is $85M. Hope they can safely exit Death Valley. Third, $MAIA data phase 2 looks promised, but cash is too few, around $10M. Keep watching.
2 · Reply
JarvisFlow
JarvisFlow May. 28 at 11:00 AM
HC Wainwright & Co. has updated their rating for XOMA Royalty ( $XOMA ) to Buy with a price target of 104.
0 · Reply
Drtymax
Drtymax May. 27 at 6:37 PM
$LADXD I’ll take 2 $XOMA shares for 1
0 · Reply
DonCorleone77
DonCorleone77 May. 27 at 12:27 PM
$XOMA Xoma purchases mezagitamab royalty, milestone rights for up to $30M XOMA Royalty and BioInvent International announced XOMA Royalty has purchased the future mezagitamab royalty and milestone interests held by BioInvent for $20M at closing, with a total transaction of up to $30M. The future royalty and milestone economics interest in mezagitamab originated from a 2003 cross-licensing agreement covering XOMA Royalty's legacy bacterial protein expression technology and BioInvent's n-CoDeR antibody library. Under the terms of XOMA Royalty's purchase of BioInvent's economic interest in mezagitamab, XOMA Royalty paid $20M to BioInvent at closing and will pay an additional $10M upon mezagitamab achieving a specific pre-defined regulatory milestone associated with receiving marketing approval in the IgA nephropathy indication from the U.S. Food and Drug Administration. With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to $16.25M from Takeda and mid-single digit royalties on future mezagitamab commercial sales.
0 · Reply
BioTechHealthX
BioTechHealthX May. 11 at 3:38 AM
$XOMA - With upcoming Phase 3 data from programs like seralutinib and ersodetug, XOMA Royalty’s royalty income could increase sharply in the coming quarters. https://biotechhealthx.com/biotech-news/investors-are-watching-xoma-ahead-of-2025s-major-clinical-readouts/
0 · Reply
Armonica423
Armonica423 May. 10 at 5:25 PM
$XOMA Big exposure for CYDY at 3 oncology conferences this week, do your dd research
0 · Reply
Zellchair
Zellchair May. 5 at 4:54 PM
$RPRX $LGND $XOMA I have written a long review of little-known peers to these companies. Under point “8. Closest comparable peers/stocks”, I write a whole paragraph about each company in tickers above, plus 4 more (Swedish and Canadian peers). Maybe someone here would appreciate reading at least that part.
0 · Reply
UNLV
UNLV Apr. 30 at 4:31 PM
Can’t see this one $XOMA https://stocktwits.com/NVDAMillionaire/message/601706454
1 · Reply
JarvisFlow
JarvisFlow Apr. 17 at 1:00 PM
Benchmark has updated their rating for XOMA Royalty ( $XOMA ) to Buy with a price target of 35.
0 · Reply
FKYOUSPIRIT
FKYOUSPIRIT Apr. 8 at 2:24 AM
$OXY $APA $CVX $XOMA Do you miss Joe now? Stock prices were so much higher What happened in just a few weeks? Tariffs killing everything?
2 · Reply
PenkeTrading
PenkeTrading Apr. 2 at 1:30 PM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of XOMA Corp. Is that bullish or bearish? $XOMA #XOMA #RsiOversold #NASDAQ
0 · Reply
JarvisFlow
JarvisFlow Mar. 28 at 12:00 PM
HC Wainwright & Co. has updated their rating for XOMA Royalty ( $XOMA ) to Buy with a price target of 104.
0 · Reply
JarvisFlow
JarvisFlow Mar. 19 at 10:30 AM
HC Wainwright & Co. updates rating for XOMA Royalty ( $XOMA ) to Buy, target set at 104.
0 · Reply
d_risk
d_risk Mar. 18 at 2:34 AM
$XOMA - XOMA Royalty Corporation Common Stock - 10K - Updated Risk Factors XOMA's 2025 10-K Risk Factors emphasize revenue risks from acquisitions, market volatility, and credit defaults, with new focus on geopolitical tensions, regulatory changes, and competition impacting financial outcomes. #Risk https://d-risk.ai/XOMA/10-K/2025-03-17
0 · Reply
lecorb
lecorb Mar. 17 at 10:13 PM
$XOMA XOMA GAAP EPS of -$1.65 misses by $0.52, revenue of $28.49M misses by $0.04M
0 · Reply
DonCorleone77
DonCorleone77 Mar. 17 at 8:56 PM
$XOMA Xoma reports Q4 net loss $4M vs net loss $20.1M last year Reports Q4 revenue $1.8M.Tom Burns, Chief Financial Officer of XOMA Royalty, commented, "Based upon the anticipated incoming cash payments from royalties alone, we have line of sight on becoming cash flow positive on a consistent basis. The transient expenses associated with the Kinnate and Pulmokine acquisitions that impacted our 2024 financial results are coming to a close. We expect our R&D and G&A expenses to normalize in the second half of 2025." Income and Revenue: XOMA Royalty recorded total income and revenues of $8.7M and $28.5 million for the fourth quarter and full year of 2024, respectively. In 2023, XOMA Royalty recorded total income and revenues of $1.8 M and $4.8 million for the fourth quarter and full year, respectively. The increase for the full year of 2024 was primarily driven by an increase in our income from purchased receivables. "Our growing commercial royalty portfolio of six assets is supported by VABYSMO JEMDA and MIPLYFFA while our Phase 3 portfolio, which now totals 11 assets, promises several key readouts in 2025, including ersodetug from Rezolute, seralutinib from Gossamer Bio, and Ovaprene from Dare Biosciences. With over $100M in cash on hand and a clear path to sustainable cashflow from royalties alone, we are well-positioned to further our goal of driving value for patients and shareholders alike."
0 · Reply
jParkz
jParkz Mar. 14 at 10:00 AM
News $XOMA Expected earnings - XOMA Royalty Corporation https://marketwirenews.com/news-releases/expected-earnings-xoma-royalty-corporation-7700690358738122.html $XOMA
0 · Reply
PenkeTrading
PenkeTrading Feb. 28 at 4:29 PM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of XOMA Corp. Is that bullish or bearish? $XOMA #XOMA #RsiOversold #NASDAQ
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 27 at 9:04 PM
$XOMA XOMA (NASDAQ:XOMA) Poised for Continued Growth as Royalty Aggregator Model Gains Traction https://beyondspx.com/article/xoma-royalty-corporation-xoma-diversifying-its-royalty-portfolio-for-sustainable-growth
0 · Reply